Incyte's 'IDO' Cancer Immunotherapy Causes Investor Scrum at ASCO '14

It's me again, still reporting from the American Society of Clinical Oncology (ASCO) annual meeting. We just got our first look at the clinical activity of Incyte's ( INCY) immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with Bristol-Myers Squibb's  ( BMY) Yervoy in melanoma patients. The Wall Street scrum around the Incyte poster was insane. 

Oh yeah, you're probably interesting in hearing about the data. Four immunotherapy-naive melanoma patients dosed with 50 mg of '360 plus Yervoy yielded 1 complete response and 1 partial response for an overall response rate of 50%. A third patient reported stable disease so the disease control rate was 75%. The Incyte press release and poster can be found here

Seeing a complete response is always a good sign, so while the number of patients treated in the 50 mg cohort is small, there's enough clinical activity here to justify running new combination studies of '360 and the PD-1 inhibitors from Bristol, Merck ( MRK) and others. 

We last saw data on '360 at the 25 mg dose when the ASCO abstracts were released in mid May.

Incyte shares rebounded big time when the '360 data were announced this afternoon.

INCY Price Chart INCY Price data by YCharts
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Apache, Incyte, Prudential, ON Semiconductor: 'Mad Money' Lightning Round

Apache, Incyte, Prudential, ON Semiconductor: 'Mad Money' Lightning Round

Playing Defense and Offense: Cramer's 'Mad Money' Recap (Tuesday 11/7/17)

Playing Defense and Offense: Cramer's 'Mad Money' Recap (Tuesday 11/7/17)

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Geron Shares Rise on Fast Track Designation -- Biotech Movers